4Front Ventures Corp
4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. It engages in the cultivation, manufacturing, distribution, and retail of cannabis and cannabis derived goods in Illinois and Massachusetts, providing integrated supply chain to serve medical and recreational markets. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix… Read more
4Front Ventures Corp (FFNTF) - Net Assets
Latest net assets as of September 2024: $-48.45 Million USD
Based on the latest financial reports, 4Front Ventures Corp (FFNTF) has net assets worth $-48.45 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($278.08 Million) and total liabilities ($326.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-48.45 Million |
| % of Total Assets | -17.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -167.64% |
| 10-Year Change | N/A |
| Growth Volatility | 921.39 |
4Front Ventures Corp - Net Assets Trend (2015–2023)
This chart illustrates how 4Front Ventures Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 4Front Ventures Corp (2015–2023)
The table below shows the annual net assets of 4Front Ventures Corp from 2015 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-51.39 Million | -281.28% |
| 2022-12-31 | $28.35 Million | -24.46% |
| 2021-12-31 | $37.53 Million | -11.07% |
| 2020-12-31 | $42.20 Million | -44.45% |
| 2019-12-31 | $75.98 Million | +862.47% |
| 2018-12-31 | $-9.96 Million | -132.12% |
| 2018-04-30 | $31.03 Million | +2361.36% |
| 2017-12-31 | $1.26 Million | +419.51% |
| 2016-12-31 | $-394.53K | -52.79% |
| 2015-12-31 | $-258.22K | -- |
Equity Component Analysis
This analysis shows how different components contribute to 4Front Ventures Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41507402122.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $375.90 Million | % |
| Total Equity | $-51.50 Million | 100.00% |
4Front Ventures Corp Competitors by Market Cap
The table below lists competitors of 4Front Ventures Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanwil Holding SA
WAR:SNW
|
$2.85 Million |
|
UPAY Inc
OTCQB:UPYY
|
$2.85 Million |
|
Willow Biosciences Inc
OTCQB:CANSF
|
$2.85 Million |
|
Amtel Holdings Bhd
KLSE:7031
|
$2.85 Million |
|
Enablence Technologies Inc
PINK:ENAFF
|
$2.85 Million |
|
Wira Global Solusi Tbk PT
JK:WGSH
|
$2.85 Million |
|
Ludwig Enterprises Inc
PINK:LUDG
|
$2.85 Million |
|
Carbine Resources Ltd
AU:CRB
|
$2.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 4Front Ventures Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 28,258,000 to -51,502,000, a change of -79,760,000 (-282.3%).
- Net loss of 91,647,000 reduced equity.
- Other factors increased equity by 11,887,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-91.65 Million | -177.95% |
| Other Changes | $11.89 Million | +23.08% |
| Total Change | $- | -282.26% |
Book Value vs Market Value Analysis
This analysis compares 4Front Ventures Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.28 | $0.01 | x |
| 2017-12-31 | $0.00 | $0.01 | x |
| 2018-04-30 | $0.17 | $0.01 | x |
| 2018-12-31 | $-0.05 | $0.01 | x |
| 2019-12-31 | $0.07 | $0.01 | x |
| 2020-12-31 | $0.08 | $0.01 | x |
| 2021-12-31 | $0.06 | $0.01 | x |
| 2022-12-31 | $0.04 | $0.01 | x |
| 2023-12-31 | $-0.08 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 4Front Ventures Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -94.06%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-79.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $63.70K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-117.52K |
| 2017 | -165.67% | -36.48% | 0.18x | 25.21x | $-2.21 Million |
| 2018 | -9.74% | -74.48% | 0.09x | 1.52x | $-6.12 Million |
| 2018 | 0.00% | -377.13% | 0.22x | 0.00x | $-51.56 Million |
| 2019 | -237.06% | -580.23% | 0.15x | 2.68x | $-188.22 Million |
| 2020 | -111.62% | -81.64% | 0.28x | 4.86x | $-51.27 Million |
| 2021 | -102.27% | -36.64% | 0.41x | 6.82x | $-42.05 Million |
| 2022 | -165.96% | -39.55% | 0.34x | 12.20x | $-49.72 Million |
| 2023 | 0.00% | -94.06% | 0.37x | 0.00x | $-86.50 Million |
Industry Comparison
This section compares 4Front Ventures Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 4Front Ventures Corp (FFNTF) | $-48.45 Million | 0.00% | N/A | $2.85 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |